Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson’s disease

Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990

Neuroinflammation in Parkinson’s disease: A target for neuroprotection?

Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984

THE CEREBROSPINAL FLUID

Merritt, H. H., FREMONT-SMITH, F., & Ayer, J. B. (1938) · The American Journal of the Medical Sciences · doi:10.1097/00000441-193804000-00024 · Cited by 880

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking

Teunissen, C. E., Petzold, A., Bennett, J. L., Berven, F. S., Brundin, L., Comabella, M., Franciotta, D., Frederiksen, J. L., Fleming, J. O., Furlan, R., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c47cc2 · Cited by 845

Blood–brain barrier dysfunction in parkinsonian midbrain in vivo

Kortekaas, R., Leenders, K. L., van Oostrom, J. C. H., Vaalburg, W., Bart, J., Willemsen, A. T. M., & Hendrikse, N. H. (2005) · Annals of Neurology · doi:10.1002/ana.20369 · Cited by 733

The Blood-Brain Barrier in Brain Homeostasis and Neurological Diseases

Weiss, N., Miller, F., Cazaubon, S., & Couraud, P.-O. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2008.10.022 · Cited by 731

Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood

Barbour, R., Kling, K., Anderson, J. P., Banducci, K., Cole, T. A., Diep, L., Fox, M., Goldstein, J. M., Soriano, F., Seubert, P. A., et al. (2008) · Neurodegenerative Diseases · doi:10.1159/000112832 · Cited by 548

Dynamics of brain-derived proteins in cerebrospinal fluid

Reiber, H. (2001) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00573-3 · Cited by 512

THE SIGNIFICANCE OF THE LEWY BODY IN THE DIAGNOSIS OF IDIOPATHIC PARKINSON'S DISEASE

Gibb, W. R. G., & Lees, A. J. (1989) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1989.tb01147.x · Cited by 325

The natural history of treated Parkinson's disease in an incident, community based cohort

Evans, J., Mason, S., Williams‐Gray, C. H., Foltynie, T., Brayne, C., Robbins, T. W., & Barker, R. (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2011.240366 · Cited by 235

Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders

Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076

The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease

Iadecola, C. (2017) · Neuron · doi:10.1016/j.neuron.2017.07.030 · Cited by 2,480

Blood-Brain Barrier: From Physiology to Disease and Back

Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312

Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases

Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609

Nanomaterial-based blood-brain-barrier (BBB) crossing strategies

Xie, J., Shen, Z., Anraku, Y., Kataoka, K., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119491 · Cited by 604

The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?

Houser, M. C., & Tansey, M. G. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-016-0002-0 · Cited by 588

Parkinson’s Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation

Matheoud, D., Sugiura, A., Bellemare-Pelletier, A., Laplante, A., Rondeau, C., Chemali, M., Fazel, A., Bergeron, J. J., Trudeau, L.-E., Burelle, Y., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.039 · Cited by 582

Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics

Petersen, M. A., Ryu, J. K., & Akassoglou, K. (2018) · Nature reviews. Neuroscience · doi:10.1038/nrn.2018.13 · Cited by 527

What does plasma CRP tell us about peripheral and central inflammation in depression?

Felger, J. C., Haroon, E., Patel, T. A., Goldsmith, D. R., Wommack, E. C., Woolwine, B. J., Le, N.-A., Feinberg, R., Tansey, M. G., & Miller, A. H. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0096-3 · Cited by 448

Structure, Function, and Regulation of the Blood-Brain Barrier Tight Junction in Central Nervous System Disorders

Lochhead, J. J., Yang, J., Ronaldson, P. T., & Davis, T. P. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00914 · Cited by 445

Age-associated Physiological and Pathological Changes at the Blood-Brain Barrier: A Review

Erdő, F., Denes, L., & de Lange, E. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16679420 · Cited by 426

Striatal Blood–Brain Barrier Permeability in Parkinson'S Disease

Gray, M. T., & Woulfe, J. M. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.32 · Cited by 409

Microglia–blood vessel interactions: a double-edged sword in brain pathologies

Dudvarski Stankovic, N., Teodorczyk, M., Ploen, R., Zipp, F., & Schmidt, M. H. H. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1524-y · Cited by 301

The Role of Innate and Adaptive Immunity in Parkinson's Disease

Kannarkat, G. T., Boss, J. M., & Tansey, M. G. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130250 · Cited by 324

Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications

Cenci, M. A. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00242 · Cited by 250

Neuroimmunological Processes in Parkinson’s Disease and their Relation to α-Synuclein: Microglia as the Referee between Neuronal Processes and Peripheral Immunity

Sánchez-Guajardo, V., Barnum, C. J., Tansey, M. G., & Romero‐Ramos, M. (2013) · ASN NEURO · doi:10.1042/an20120066 · Cited by 246

Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease

Zhang, Q.-S., Heng, Y., Mou, Z., Huang, J.-Y., Yuan, Y.-H., & Chen, N.-H. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.49 · Cited by 208

Penetration of PFASs Across the Blood Cerebrospinal Fluid Barrier and Its Determinants in Humans

Wang, J., Pan, Y., Cui, Q., Yao, B., Wang, J., & Dai, J. (2018) · Environmental Science & Technology · doi:10.1021/acs.est.8b04550 · Cited by 197

Cerebrospinal fluid β‐glucocerebrosidase activity is reduced in parkinson's disease patients

Parnetti, L., Paciotti, S., Eusebi, P., Dardis, A., Zampieri, S., Chiasserini, D., Tasegian, A., Tambasco, N., Bembi, B., Calabresi, P., et al. (2017) · Movement Disorders · doi:10.1002/mds.27136 · Cited by 185

Blood–brain barrier alterations and their impact on Parkinson’s disease pathogenesis and therapy

Lau, K., Kotzur, R., & Richter, F. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00430-z · Cited by 174

Increased CSF biomarkers of angiogenesis in Parkinson disease

Janelidze, S., Lindqvist, D., Francardo, V., Hall, S., Zetterberg, H., Blennow, K., Adler, C. H., Beach, T. G., Serrano, G. E., van Westen, D., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002151 · Cited by 150

Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease

Hsiao, H., Chiu, F., Chen, C., Wu, Y., Chen, H., Chen, Y., Kuo, H., & Chern, Y. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu151 · Cited by 135

The current state of biomarkers of mild traumatic brain injury

Kim, H., Tsao, J. W., & Stanfill, A. G. (2018) · JCI Insight · doi:10.1172/jci.insight.97105 · Cited by 127

Human α-synuclein overexpression in a mouse model of Parkinson’s disease leads to vascular pathology, blood brain barrier leakage and pericyte activation

Elabi, O. F., Gaceb, A., Carlsson, R., Padel, T., Soylu-Kucharz, R., Cortijo, I., Li, W., Li, J., & Paul, G. (2021) · Scientific Reports · doi:10.1038/s41598-020-80889-8 · Cited by 131

CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson’s disease

Chung, Y. C., Shin, W.-H., Baek, J. Y., Cho, E. J., Baik, H. H., Kim, S. R., Won, S.-Y., & Jin, B. K. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.100 · Cited by 126

The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson’s disease

Jacquet, A. D. R., Alpaugh, M., Denis, H. L., Tancredi, J. L., Boutin, M. E., Decaestecker, J., Beauparlant, C., Herrmann, L., Saint‐Pierre, M., Parent, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39038-8 · Cited by 126

CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients

Skillbäck, T. B., Delsing, L., Synnergren, J., Mattsson, N., Janelidze, S., Nägga, K., Kilander, L., Hicks, R., Wimo, A. B., Winblad, B. G., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.028 · Cited by 127

Astrocytic VEGFA : An essential mediator in blood–brain‐barrier disruption in Parkinson's disease

Lan, G., Wang, P., Chan, R. B., Liu, Z., Yu, Z., Liu, X., Yang, Y., & Zhang, J. (2022) · Glia · doi:10.1002/glia.24109 · Cited by 122

Fluid biomarkers in frontotemporal dementia: past, present and future

Swift, I. J., Sogorb-Esteve, A., Heller, C., Synofzik, M., Otto, M., Graff, C., Galimberti, D., Todd, E., Heslegrave, A. J., van der Ende, E. L., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323520 · Cited by 122

Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review

Andersen, A. D., Binzer, M., Stenager, E., & Gramsbergen, J. B. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12590 · Cited by 122

Engineered nanomaterials that exploit blood-brain barrier dysfunction for delivery to the brain

Wu, J. R., Hernández, Y. M., Miyasaki, K. F., & Kwon, E. J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114820 · Cited by 108

Confounding Parameters in Preclinical Assessment of Blood–Brain Barrier Permeation: An Overview With Emphasis on Species Differences and Effect of Disease States

Deo, A. K., Theil, F., & Nicolas, J.-M. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300570z · Cited by 105

Distinct Patterns of Cerebral Extravasation by Evans Blue and Sodium Fluorescein in Rats

Yen, L. F., Wei, V. C., Kuo, E. Y., & Lai, T. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068595 · Cited by 106

Microvascular Changes in Parkinson’s Disease- Focus on the Neurovascular Unit

Paul, G., & Elabi, O. F. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.853372 · Cited by 98

Cerebrospinal fluid proteomics implicates the granin family in Parkinson’s disease

Rotunno, M. S., Lane, M., Zhang, W., Wolf, P., Oliva, P., Viel, C., Wills, A.-M., Alcalay, R. N., Scherzer, C. R., Shihabuddin, L. S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-59414-4 · Cited by 94

MMP-3 Contributes to Nigrostriatal Dopaminergic Neuronal Loss, BBB Damage, and Neuroinflammation in an MPTP Mouse Model of Parkinson’s Disease

Chung, Y. C., Kim, Y.-S., Bok, E., Yune, T. Y., Maeng, S., & Jin, B. K. (2013) · Mediators of Inflammation · doi:10.1155/2013/370526 · Cited by 94

Eryptosis as a marker of Parkinson's disease

Pretorius, E., Swanepoel, A. C., Buys, A. V., Vermeulen, N., Duim, W., & Kell, D. B. (2014) · Aging · doi:10.18632/aging.100695 · Cited by 95

Gut Inflammation in Association With Pathogenesis of Parkinson’s Disease

Chen, Q.-Q., Haikal, C., Li, W., & Li, J. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00218 · Cited by 88

Blood–Brain Barrier and Neurodegenerative Diseases—Modeling with iPSC-Derived Brain Cells

Wu, Y., Sonninen, T.-M., Peltonen, S., Koıstınaho, J., & Lehtonen, Š. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147710 · Cited by 91

Potential role of gut microbiota and tissue barriers in Parkinson's disease and amyotrophic lateral sclerosis

Fang, X. (2015) · International Journal of Neuroscience · doi:10.3109/00207454.2015.1096271 · Cited by 84

COVID-19: dealing with a potential risk factor for chronic neurological disorders

Schirinzi, T., Landi, D., & Liguori, C. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10131-y · Cited by 78

Age-dependent changes at the blood-brain barrier. A Comparative structural and functional study in young adult and middle aged rats

Bors, L. A., Tóth, K., Tóth, E. Z., Bajza, Á., Csorba, A., Szigeti, K., Máthé, D., Perlaki, G., Orsi, G., Tóth, G. K., et al. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.03.001 · Cited by 81

Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson’s Disease

Kuštrimović, N. Z., Marino, F., & Cosentino, M. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181009161048 · Cited by 74

In vitro models and systems for evaluating the dynamics of drug delivery to the healthy and diseased brain

Modarres, H. P., Janmaleki, M., Novin, M., Saliba, J., Moussa, F. E. H., Charan, M. R., Seyfoori, A., SadAbadi, H., Vandal, M., Nguyen, M. D., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.024 · Cited by 77

Deciphering albumin-directed drug delivery by imaging

Hu, H., Quintana, J. M., Weissleder, R., Parangi, S., & Miller, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114237 · Cited by 71

Intracarotid Infusion of Mesenchymal Stem Cells in an Animal Model of Parkinson's Disease, Focusing on Cell Distribution and Neuroprotective and Behavioral Effects

Cerri, S., Greco, R., Levandis, G., Ghezzi, C., Mangione, A. S., Armentero, M., Bonizzi, A., Avanzini, M. A., Maccario, R., & Blandini, F. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0023 · Cited by 72

Peripheral-Central Neuroimmune Crosstalk in Parkinson's Disease: What Do Patients and Animal Models Tell Us?

Armentero, M., Cerri, S., & Blandini, F. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00232 · Cited by 75

The molecular anatomy and functions of the choroid plexus in healthy and diseased brain

Kratzer, I., Ek, C. J., & Stolp, H. B. (2020) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2020.183430 · Cited by 74

Exploiting BBB disruption for the delivery of nanocarriers to the diseased CNS

Umlauf, B. J., & Shusta, E. V. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.01.013 · Cited by 67

Unique signatures of stress-induced senescent human astrocytes

Simmnacher, K., Krach, F., Schneider, Y., Alecu, J. E., Mautner, L., Klein, P., Roybon, L., Prots, I., Xiang, W., & Winner, B. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113466 · Cited by 65

Blood-brain barrier models: Rationale for selection

Hanafy, A. S., Dietrich, D., Fricker, G., & Lamprecht, A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113859 · Cited by 59

Blood–brain barrier opening with focused ultrasound in experimental models of Parkinson's disease

Karakatsani, M. E., Blesa, J., & Konofagou, E. E. (2019) · Movement Disorders · doi:10.1002/mds.27804 · Cited by 58

Contra-Directional Expression of Plasma Superoxide Dismutase with Lipoprotein Cholesterol and High-Sensitivity C-reactive Protein as Important Markers of Parkinson’s Disease Severity

Yang, W., Chang, Z., Que, R., Weng, G., Deng, B., Wang, T., Huang, Z., Xie, F., Wei, X., Yang, Q., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00053 · Cited by 55

The hunt for brain Aβ oligomers by peripherally circulating multi-functional nanoparticles: Potential therapeutic approach for Alzheimer disease

Mancini, S., Minniti, S., Gregori, M., Sancini, G., Cagnotto, A., Couraud, P., Ordóñez‐Gutiérrez, L., Wandosell, F. G., Salmona, M., & Re, F. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.09.003 · Cited by 54

Parkinson's and Lewy body dementia CSF biomarkers

Parnetti, L., Paciotti, S., Farotti, L., Bellomo, G., Sepe, F. N., & Eusebi, P. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.04.078 · Cited by 56

Homologous HSV1 and alpha-synuclein peptides stimulate a T cell response in Parkinson's disease

Caggiu, E., Paulus, K. S., Galleri, G., Arru, G., Manetti, R., Sechi, G., & Sechi, L. A. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.06.004 · Cited by 53

The choroid plexus epithelium as a novel player in the stomach-brain axis during Helicobacter infection

Gorlé, N., Blaecher, C., Bauwens, E., Vandendriessche, C., Balusu, S., Vandewalle, J., Van Cauwenberghe, C., Van Wonterghem, E., Van Imschoot, G., Liu, C., et al. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.12.010 · Cited by 49

Cerebrospinal fluid biomarkers profile of idiopathic normal pressure hydrocephalus

Schirinzi, T., Sancesario, G. M., Lazzaro, G. D., D’Elia, A., Imbriani, P., Scalise, S., & Pisani, A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1842-z · Cited by 49

Oxidative stress in the choroid plexus contributes to blood–cerebrospinal fluid barrier disruption during sepsis development

Goldim, M. P. D. S., Danielski, L. G., Rodrigues, J. F., Joaquim, L. D. S., Garbossa, L., de Oliveira, A. N., Metzker, K. L. L., Giustina, A. D., Cardoso, T., Barichello, T., et al. (2018) · Microvascular Research · doi:10.1016/j.mvr.2018.12.001 · Cited by 48

Cerebrospinal Fluid Biomarkers in Parkinson’s Disease: A Critical Overview of the Literature and Meta-Analyses

Katayama, T., Sawada, J., Takahashi, K., & Yahara, O. (2020) · Brain Sciences · doi:10.3390/brainsci10070466 · Cited by 48

Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease

Reich, N., & Hölscher, C. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.614828 · Cited by 48

Human serum albumin in neurodegeneration

Shojai, S., Rohani, S., Moosavi‐Movahedi, A. A., & Habibi-Rezaei, M. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2021-0165 · Cited by 49

Dissecting the Interactions between Human Serum Albumin and α-Synuclein: New Insights on the Factors Influencing α-Synuclein Aggregation in Biological Fluids

Bellomo, G., Bologna, S., Cerofolini, L., Paciotti, S., Gatticchi, L., Ravera, E., Parnetti, L., Fragai, M., & Luchinat, C. (2019) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.9b02381 · Cited by 47

A Clinical and Biochemical Analysis in the Differential Diagnosis of Idiopathic Normal Pressure Hydrocephalus

Schirinzi, T., Sancesario, G. M., Ialongo, C., Imbriani, P., Madeo, G., Toniolo, S., Martorana, A., & Pisani, A. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00086 · Cited by 47

Blood-Brain Barrier Dysfunction in Small Vessel Disease Related Intracerebral Hemorrhage

Freeze, W. M., Jacobs, H. I. L., Schreuder, F. H. B. M., van Oostenbrugge, R. J., Backes, W. H., Verhey, F. R. J., & Klijn, C. J. M. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00926 · Cited by 45

Dietary cholesterol, fats and risk of Parkinson's disease in the Singapore Chinese Health Study

Tan, L., Methawasin, K., Tan, E., Tan, J. H., Au, W., Yuan, J., & Koh, W. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-310065 · Cited by 42

Molecular and Cellular Interactions in Pathogenesis of Sporadic Parkinson Disease

Долгачева, Л. П., Зинченко, В. П., & Goncharov, N. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113043 · Cited by 43

Biofluid markers of blood-brain barrier disruption and neurodegeneration in Lewy body spectrum diseases: A systematic review and meta-analysis

Wong, Y. Y., Wu, C., Yu, D., Kim, E., Wong, M., Elez, R., Zebarth, J., Ouk, M., Tan, J., Liao, J., et al. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.06.004 · Cited by 41

Microbiome–gut–brain dysfunction in prodromal and symptomatic Lewy body diseases

Ryman, S. G., Vakhtin, A. A., Richardson, S. P., & Lin, H. C. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11461-9 · Cited by 39

The neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and neutrophil-to-high-density-lipoprotein ratio are correlated with the severity of Parkinson’s disease

Li, F., Weng, G., Zhou, H., Zhang, W., Deng, B., Luo, Y., Xi, T., Deng, M., Guo, H., Zhu, S., et al. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1322228 · Cited by 37

α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson’s Disease Pathogenesis

Butkovich, L. M., Houser, M. C., & Tansey, M. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00626 · Cited by 39

Temporal analysis of blood–brain barrier disruption and cerebrospinal fluid matrix metalloproteinases in rhesus monkeys subjected to transient ischemic stroke

Zhang, Y., Fan, F., Zeng, G., Zhou, L., Zhang, Y., Zhang, J., He, J., Zhang, T., Su, D., Yang, C., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16680221 · Cited by 36

Age-dependent increase of blood–brain barrier permeability and neuron-binding autoantibodies in S100B knockout mice

Wu, H., Brown, E. V., Acharya, N. K., Appelt, D. M., Marks, A., Nagele, R. G., & Venkataraman, V. (2016) · Brain Research · doi:10.1016/j.brainres.2016.02.026 · Cited by 37

Nanotechnology to Overcome Blood–Brain Barrier Permeability and Damage in Neurodegenerative Diseases

Jiménez, A., Estudillo, E., Guzmán‐Ruiz, M. A., Herrera, N., Victoria-Acosta, G., Cortés-Malagón, E. M., & López-Ornelas, A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030281 · Cited by 36

Increased albumin CSF/serum ratio in dementia with Lewy bodies

Llorens, F., Schmitz, M., Gloeckner, S. F., Kaerst, L., Hermann, P., Schmidt, C., Varges, D., & Zerr, I. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.10.011 · Cited by 34

The Effect of Human Umbilical Cord Mesenchymal Stromal Cells in Protection of Dopaminergic Neurons from Apoptosis by Reducing Oxidative Stress in the Early Stage of a 6-OHDA-Induced Parkinson’s Disease Model

Chi, H., Guan, Y., Li, F., & Chen, Z. (2019) · Cell Transplantation · doi:10.1177/0963689719891134 · Cited by 34

The role of glia in Parkinson's disease: Emerging concepts and therapeutic applications

Kuter, K. Z., Cenci, M. A., & Carta, A. R. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2020.02.004 · Cited by 31

Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression

Christine, C. W., Auinger, P., Saleh, N., Tian, M., Bottiglieri, T., Arning, E., Tran, N. K., Ueland, P. M., Green, R., & the Parkinson Study Group—DATATOP Investigators (2020) · Movement Disorders · doi:10.1002/mds.28073 · Cited by 30

The Complexity of the Blood-Brain Barrier and the Concept of Age-Related Brain Targeting: Challenges and Potential of Novel Solid Lipid-Based Formulations

Sommonte, F., Arduino, I., Racaniello, G. F., Lopalco, A., Lopedota, A., & Denora, N. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.08.029 · Cited by 29

Towards early detection of neurodegenerative diseases: A gut feeling

Makdissi, S., Parsons, B., & Cara, F. D. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1087091 · Cited by 28

The Functional Roles and Applications of Immunoglobulins in Neurodegenerative Disease

Sim, K.-Y., Im, K. C., & Park, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155295 · Cited by 24

Investigating the Association of ApoE Genotypes with Blood-Brain Barrier Dysfunction Measured by Cerebrospinal Fluid-Serum Albumin Ratio in a Cohort of Patients with Different Types of Dementia

Karch, A., Manthey, H. G., Ponto, C., Hermann, P., Heinemann, U., Schmidt, C., & Zerr, I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084405 · Cited by 23

Coordinating Global Multi-Site Studies of Military-Relevant Traumatic Brain Injury: Opportunities, Challenges, and Harmonization Guidelines

Tate, D. F., Dennis, E. L., Adams, J. T., Adamson, M. M., Belanger, H. G., Bigler, E. D., Bouchard, H. C., Clark, A. L., Delano‐Wood, L., Disner, S. G., et al. (2021) · Brain Imaging and Behavior · doi:10.1007/s11682-020-00423-2 · Cited by 23

Ceruloplasmin Deamidation in Neurodegeneration: From Loss to Gain of Function

Zanardi, A., & Alessio, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020663 · Cited by 25

Substance P and its tachykinin NK1 receptor: a novel neuroprotective target for Parkinson′s disease

Vink, R., & Thornton, E. (2015) · Neural Regeneration Research · doi:10.4103/1673-5374.165505 · Cited by 21

Unlocking the potential of low-molecular-weight (Poly)phenol metabolites: Protectors at the blood-brain barrier frontier

Marques, D., Moura-Louro, D., Silva, I. P., Matos, S., dos Santos, C. N., & Figueira, I. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105836 · Cited by 21

The Breakdown of Neurovascular Barriers: Molecular Mechanisms of Tight Junction Dysfunction

Gopal, S. S., Kaur, M., Lanzkron, S., & Srivastava, A. K. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05592-z · Cited by 20

Nanomedicine against Alzheimer’s and Parkinson’s Disease

Tandon, A., Singh, S. J., & Chaturvedi, R. K. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201021140904 · Cited by 20

The Relationships Among Metal Homeostasis, Mitochondria, and Locus Coeruleus in Psychiatric and Neurodegenerative Disorders: Potential Pathogenetic Mechanism and Therapeutic Implications

Nakagawa, Y., & Yamada, S. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01234-3 · Cited by 20

Metal homeostasis disturbances in neurodegenerative disorders, with special emphasis on Creutzfeldt-Jakob disease – Potential pathogenetic mechanism and therapeutic implications

Nakagawa, Y., & Yamada, S. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107455 · Cited by 18

Features of Plasma Homocysteine, Vitamin B12, and Folate in Parkinson's Disease: An Updated Meta-Analysis

Liu, Y., Gou, M., & Guo, X. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2205115 · Cited by 17

AnIn VivoMicrodialysis Study of FLZ Penetration through the Blood-Brain Barrier in Normal and 6-Hydroxydopamine Induced Parkinson’s Disease Model Rats

Hou, J., Liu, Q., Li, Y., Sun, H., & Zhang, J. (2014) · BioMed Research International · doi:10.1155/2014/850493 · Cited by 17

Alzheimer's disease pathology: pathways between chronic vascular risk factors and blood-brain barrier dysfunction in a cohort of patients with different types of dementia

Gan, J., Yang, X., Zhang, G., Li, X., Liu, S., Zhang, W., & Ji, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1088140 · Cited by 17

Multifunctional Nanoparticles for Successful Targeted Drug Delivery across the Blood-Brain Barrier

Vieira, D. B., & Gamarra, L. F. (2018) · InTech eBooks · doi:10.5772/intechopen.76922 · Cited by 17

Cerebrospinal-fluid biomarkers for predicting phenoconversion in patients with isolated rapid-eye movement sleep behavior disorder

Fernandes, M., Maio, S., Eusebi, P., Placidi, F., Izzi, F., Spanetta, M., Masi, C. D., Lupo, C., Calvello, C., Nuccetelli, M., et al. (2023) · SLEEP · doi:10.1093/sleep/zsad198 · Cited by 15

Effects of Low-Level Blast on Neurovascular Health and Cerebral Blood Flow: Current Findings and Future Opportunities in Neuroimaging

Kilgore, M. O., & Hubbard, W. B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010642 · Cited by 15

Association between C-reactive protein-albumin ratio and overall survival in Parkinson's disease using publicly available data: A retrospective cohort study

Gao, M., Zhang, C., Gao, L., Sun, S., Song, L., & Liu, S. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12671 · Cited by 15

Do Bacterial Outer Membrane Vesicles Contribute to Chronic Inflammation in Parkinson’s Disease?

Koukoulis, T. F., Beauchamp, L. C., Kaparakis‐Liaskos, M., McQuade, R. M., Purnianto, A., Finkelstein, D. I., Barnham, K. J., & Vella, L. J. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230315 · Cited by 14

Gut microbiota and inflammation in Parkinson’s disease: Pathogenetic and therapeutic insights

Guo, T., & Chen, L. (2022) · European Journal of Inflammation · doi:10.1177/1721727x221083763 · Cited by 14

Radioligand binding analysis of α2 adrenoceptors with [11C]yohimbine in brain in vivo: Extended Inhibition Plot correction for plasma protein binding

Phan, J.-A., Landau, A. M., Jakobsen, S., Wong, D. F., & GJEDDE, A. H. (2017) · Scientific Reports · doi:10.1038/s41598-017-16020-1 · Cited by 14

Integrity of the blood–cerebrospinal fluid barrier in early Parkinson's disease

Häussermann, P., Kuhn, W., Przuntek, H., & Müller, T. H. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01574-9 · Cited by 42

Cerebrospinal-fluid Alzheimer’s Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson’s Disease Patients

Liguori, C., Olivola, E., Pierantozzi, M., Cerroni, R., Galati, S., Saviozzi, V., Mercuri, N. B., & Stefani, A. (2017) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527316666161205123123 · Cited by 20

Alterations of Transferrin and Prealbumin in Cerebrospinal Fluid in Parkinson’s Disease

Arai, M., Orimo, S., Kurosawa, T., Hiyamuta, E., Nakayama, T., Nakatsu, M., & Shiba, K. S. (1990) · Advances in behavioral biology · doi:10.1007/978-1-4684-5847-3_9

Increased blood-brain barrier permeability is associated with dysfunctional α band connectivity in early-stage Parkinson’s disease

Conti, M., Ferrari, V., Pierantozzi, M., Simonetta, C., Carparelli, F., D’Angelo, V., Bagetta, S., Giuliano, F. D., Mercuri, N. B., Schirinzi, T., et al. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-03002-1 · Cited by 5

Blood-brain barrier dysfunction and altered choroid plexus contrast kinetics in Parkinson’s disease

Fajerzstein, S., Eshed, G. M., Mirloo, S., Rabinowich, A., Thaler, A., Mirelman, A., Shiner, T., Giladi, N., Alcalay, R. N., Orad, R. I., et al. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-026-00890-7